ArticleCancers2023

Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.

Jaume Mora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.